Supplements for Controlling Resistance to Insulin (SCORE)

The purpose of this study is to evaluate the effects of a combination of hydroxcycitrate (HCA) and niacin-bound chromium, in conjunction with nutrition education, over a twelve week period. Participants will be evaluated with regard to BMI, percent body fat, insulin activity, and hunger.

Study Overview

• Status: Terminated
• Conditions: Obesity; Diabetes Mellitus, Type 2
• Intervention / Treatment: Drug: nutrition education plus active supplement; Drug: nutrition education plus inactive supplement

Detailed Description

The prevalence of obesity among youth has increased dramatically in recent years. Parallel to the increased rates of pediatric obesity, overweight children present clinically with adiposity related comorbidities such as insulin resistance and type 2 diabetes. The prevailing recommendations for overweight youth are to increase physical activity levels and limit energy intake in order to improve body composition. Currently there is little empirical evidence to support the efficacy of these recommendations. Alternatively, evidence in adults suggests that nutritional supplementation with (-) hydroxycitric acid (HCA), an organic acid found naturally in citrus fruits, and chromium may lead to favorable changes in body composition and improve glucose regulation. To date, these issues have not been tested in youth. Therefore, the purpose of the present investigation is to examine the effects of a nutritional education program combined with either HCA + chromium or placebo on measures of body composition and glucose regulation in overweight adolescents.

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • USC - Preventive Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years to 17 years (Child)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age

  • All subjects will be between 13 and 17 years of age

• Overweight

  • All subjects will be overweight as defined by an age & sex-specific body mass index ≥ 85th percentile based on CDC BMI growth charts [US Department of Health and Human Services, 2000], calculated by Epi Info Software, version 3.3.

Exclusion Criteria:

• Presently taking any prescribed medication(s) or diagnosed with any syndrome or disease that could influence dietary intake, body composition and fat distribution, or insulin action or secretion.
• Previously diagnosed with any major illness since birth (e.g. sever intrauterine growth retardation, chronic birth asphyxia, cancer).
• Children with type 1 and/or type 2 diabetes will be excluded are referred to a physician.
• Currently involved with any dietary, exercise, or weight loss program or have been in the 6 months prior to participation.
• Unexplained weight loss or gain in the prior six months.
• Oral contraception use in sexually active females
• Children who live further than 20 miles away from the USC Health Science Campus (HSC).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 1 - nutrition education plus active supplement; nutrition education plus active supplement	Drug: nutrition education plus active supplement; After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes. Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal.; Other Names: none known
Placebo Comparator: 2 - nutrition education plus inactive supplement; nutrition education plus inactive supplement	Drug: nutrition education plus inactive supplement; After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes. Active and inactive supplements will be identical in appearance and taste.; Other Names: none known

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body Mass Index	Change in Body Mass Index measurement at baseline and 12 weeks	measured at baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Insulin Activity	Change in insulin activity measured at baseline and 12 weeks	Measured at baseline and 12 weeks
Percent Body Fat	Change in percent body fat measured at baseline and 12 weeks	Measured at baseline and 12 weeks
Hunger	Change in hunger score using Likert scale measured at baseline and 12 weeks	Measured at baseline and 12 weeks

Collaborators and Investigators

• Sponsor: University of Southern California
• Collaborators: InterHealth Nutraceuticals, Inc.
• Investigators: Principal Investigator: Michael I Goran, PhD, University of Southern California

Study record dates

Study Major Dates

• Study Start: February 1, 2008
• Primary Completion (Actual): August 1, 2008
• Study Completion (Actual): August 1, 2008

Study Registration Dates

• First Submitted: June 16, 2008
• First Submitted That Met QC Criteria: June 17, 2008
• First Posted (Estimated): June 18, 2008

Study Record Updates

• Last Update Posted (Actual): June 11, 2024
• Last Update Submitted That Met QC Criteria: May 16, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: SCORE1